An electric wheelchair is a wheelchair that uses electric motor rather than manual power for functioning. Electric wheelchairs are useful for those who cannot use manual wheelchairs or who need to use wheelchairs for considerable long distance. These can be usually used by people who are physically challenged and also senior citizens with problems related to mobility. Design of a wheelchair consists of the following elements: battery, drive system, controller, and seat. The electric motors of these chairs are usually powered by 12-80 ampere per hour of rechargeable deep-cycle batteries. Some users are not able to use hand controllers and therefore, various other options are made available, for instance, sip and puff controllers, which works by blowing into the sensor. Electric wheelchair can also be used by people suffering from diseases such as chronic diseases and asthma. Electric wheelchair offers special features such as tilting capabilities, elevation of seats, and leg elevation. Electric wheelchair can also be dissembled and folded to take it around wherever needed. These are light in weight i.e. less than 100 lbs, and are also compact in size, which is ideal for narrow doorways and small spaces.
Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1758 Electric Wheelchair Market Drivers:- Growth of the electric wheelchair market is driver by increasing launches of new products with advanced technologies such as automatic folding wheelchair. For instance, in June 2018, Quantum Rehab launched Edge 3, the most advanced power chair, with an upgraded SRS (Smooth Ride Suspension). SRS provides stability, comfortable, and smooth ride. Its standard features include USB charger, drive wheel color accents, and front and rear fender lights. In 2017, Ivacare Corporation, a U.S.-based company, launched TDX-SP2 ELECTRIC WHEELCHAIR. This electric wheel chair has LiNX technology and advanced positioning. LiNX technology electronic system includes wireless programming and remote monitoring, which enables better clinical evaluations and touch screen display. This technology also enables easy intuitive programming and also hassle free functioning of the equipment for its customers. Other factors, which are expected to boost growth of the electric wheelchair market are rising geriatric population, rising awareness related to benefits of use of automated wheelchairs over manual wheelchairs, and increasing prevalence of chronic disorders in geriatric population. According to a survey conducted by Population Reference Bureau in 2016, there were over 46 million senior citizens of the age 65 and above in U.S. About 48% of this aging population are disabled due to age factor and chronic diseases. According to a survey conducted by the U.S. Census Bureau in 2017, around 40 million people in the U.S. are physically challenged. Moreover, according to a survey conducted by Center for Disease Control and Prevention in 2016, over 117 million people were diagnosed with chronic disorders. All these factors are expected to support growth of the electric wheelchair market over the forecast period (2018-2026). Electric Wheelchair Market Regional Analysis:- North America is expected to hold dominant position in the global electric wheelchair market, and is also expected to exhibit a significant growth rate, owing to increasing launches of novel products in the market. For instance, in April 2018, Quantum Rehab, a U.S.-based company, launched Kozmo and Kozmo Portable. This device is especially made for children. The size of Kozmo Portable electric wheelchair is compact and easy to carry. It helps in fast transport and is convenient for parents and children. Moreover, in April 2018, Quantum Rehab launched products including TRU-BALANCE 3 and TRU- BALANCE FLEX. Such new range of products is expected to fuel growth of the electric wheelchair market. Furthermore, Medicare, national (U.S.) health insurance program provides reimbursements on buying an electric wheel chair. The patient pays 20% of the amount mentioned for a given product and Medicare pays the remaining 80%. Such reimbursement plans can boost adoption of the electric wheel chair market in North America. Asia Pacific is also expected to witness high growth in the global electric wheel chair market, due to rise of chronic diseases in geriatric population and increasing launch of electric wheel chairs with advanced technology. According to a survey conducted by National Institutes of health in 2015, cardiovascular disease is rising in Asian population. Cardiovascular disease has caused approximately 52% of deaths in India. For instance, in 2017, Whill Inc., a Japan-based company, launched Model M. This device has omni-wheel technology, which can be used on rough terrain. It also has a compact size and its agile steering can easily navigate in narrow and tight spaces. Such innovations are expected to fuel growth of the electric wheelchair market. Electric Wheelchair Market Key Players:-
Electric Wheelchair Market Taxonomy:- By Product Type:-
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]
0 Comments
Closed blood sampling system is a closed, needle free blood sampling system that reduces blood waste and minimizes the risk of transmission of infectious diseases. Closed blood sampling system aims to increase the efficiency of the blood sampling process, especially in the cases of critically ill patients suffering from severe injuries or trauma. The closed blood sampling system has a reservoir, which allows blood storage and minimize repeated blood isolation from the site of sampling such as antecubital area, hand or wrist or foot. The unused blood in the reservoir can be re-infused into the same patient. The global closed blood sampling market is driven by factors such as rising incidence of surgeries and trauma as well as advantages of closed blood sampling system over the conventional techniques.
Closed blood sampling systems require less blood as compared to open blood sampling system, thus leading to less blood loss in patients. Moreover, implementing closed blood sampling systems significantly reduces iatrogenic anemia, thereby reducing the necessity for blood transfusions and minimizing possible risk of negative transfusion effects. However, lack of implementation of this process and lack of professionals are expected to hinder growth of closed blood sampling system market. Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/1642 Closed Blood Sampling System Market Drivers Increasing number of surgical procedures is a major factor driving growth of global closed blood sampling system market. According to the estimation of the World Health Organization, 266.2 to 359.5 million surgeries were performed in 2012, which was around 38% higher as compared to the previous years and is expected to increase in the near future. Therefore, increasing number of surgeries and emergency cases, and high demand for blood transfusion increases the demand for closed blood sampling system. Moreover, studies by the National Center for Biotechnology Information (NCBI) reported that the patients admitted in ICU are majorly anemic and around 30 - 37% of the patients receive blood transfusion while admitted in ICU, which also shows the rising need for closed blood sampling system. In critically ill patients and patients under observation in ICU, blood sampling is frequently done to monitor the hemodynamics. In conventional blood sampling systems, the blood sample is withdrawn by removal of stopcock cap, which increases the risk of acquired blood stream infection during sampling. Moreover, the unused blood is wasted in the case of conventional sampling method. Closed blood sampling system is a solution to these problems. Furthermore, the National Center for Biotechnology Information (NCBI) article suggests that the hemoglobin and hematocrit counts shows minimal fluctuations when blood sampling is done by closed blood sampling system. Closed blood sampling systems are also used in pediatric patients, owing to easy implementation, low cost, and significant reduction in blood loss. The patients in the intensive care units (ICU) receive blood transfusion to treat low hemoglobin levels in patients with critical illness. However, improper blood transfusion methods are mostly associated with increased risk of morbidity and mortality. Various government regulatory organizations have proposed guidelines to decrease the use of blood transfusions. For instance, the Canadian Medical Association (CMA) released guidelines in 2008 in their Canadian Medical Association Journal (CMAL), which was published in January 2008, to minimize the use of blood transfusion in critically ill patients and closed blood sampling systems would be a method for complying with these regulations. Closed Blood Sampling System Market - Regional Analysis On the basis of region, closed blood sampling systems market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds dominant position in closed blood sampling system market, followed by Asia Pacific. Increasing demand for blood transfusions, owing to the increasing number of surgery or injury cases is driving growth of closed blood sampling system market in North America. For instance, according to the American National Red Cross, a humanitarian organization, around 21 million blood components are transfused every year in the U.S. Increasing demand for closed blood sampling systems with the establishment of new hospitals, specialty clinics, and blood banks, and increasing demand for the usage of blood components, owing to the increasing number of blood transfusion procedures is fueling growth of closed blood sampling systems market in Asia Pacific. For instance, according to the National AIDS Control Organization (NACO) 2014 data findings, demand for blood and blood components in India is around 1% of the total population, which is around 12 million blood units (1% of 1.2 billion populations). Moreover, according to the Department of Control (DAC), India: 2013, the annual requirement of blood was estimated to be 80 lakh units of blood between 2012 and 2013. Closed Blood Sampling System Market Competitive Landscape Some of the key players operating in the closed blood sampling system market include Edwards Lifesciences Crop, ICU Medical, Inc., Smiths Medical, CardioMed Supplies Inc., Argon Medical Devices, Inc., Utah Medical Products, Inc., fannin Ltd., Velano Vascular, Inc., Ashcon International Inc., and Merit Medical Systems, Inc. Key players in the market are focusing on organic growth strategies, in order to enhance its market share and retain its competence in the market. For instance, in January 2016, Velano Vascular, Inc., a medical device company that manufactures needle-free, vascular device for blood collection received the U.S. FDA approval for its updated version of needle-free blood draw device. The new Velano device is designed to reduce blood draw related anxiety and discomfort in patients and also provides a safer work environment for healthcare professionals. Inquire Here Before Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1642 Closed Blood Sampling System Market Taxonomy: By Product Type:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected] Advancements in the field of biotechnology and pharmaceuticals, in order to identify active ingredients in the form of drugs through drug discovery process, is gradually gaining pace in the market. This drug discovery process involves screening of chemical libraries, identification of the active ingredients for a natural remedy or by serendipitous discovery. Emergence of new diseases, which include viral or infectious diseases leads to high demand for drug discovery for these conditions. However, development of drugs is complex, costly, and risky process.
Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1631 The objective of drug discovery is to recognize the investigational drug success rates by stages, pre-clinical studies, investigational new drug application-Phase I, Phase II, Phase III studies, new drug application, and phase IV studies. The success during drug discovery process is very low, as according to data published by Journal Research & Review 2016. According to the data, it was estimated that among 5,000-10,000 drug discovery screening, only 250 enter the preclinical testing and 5 enter the clinical testing and only 1 drug is approved by the regulatory body, which takes roughly 5-10 years. Drug Discovery Market Dynamics: A patent cliff provides an opportunity for manufactures to collaborate and participate in current drug discovery model to sustain in the market. Manufacturers such as, Eli Lilly, Pfizer, Takeda, Bristol-Myers Squibb and Gilead lost their patent in 2017, with some of their respective big sellers that cover a range of indications such as multiple sclerosis, HIV, erectile dysfunction, and cancer. Such patent loss forces companies to introduce innovative products to retain their revenues and increase their revenue. After patent expiration, generic manufacturers enter the market and provide drugs that are equivalent to the innovator’s drugs, however, at a significantly lower price. Therefore, manufacturers are focusing on developing new and innovative products to sustain in the competitive market. Increasing prevalence of wide range of disease such as cancer, cardiovascular, and CNS-related disorders with patent expiration of blockbuster drugs are some of the driving factors for growth of the drug discovery market. According to the World Cancer Research Fund International, 2015, an estimated 124,000 new cases of myeloma were diagnosed globally in 2015, which accounted for 0.8% of the total cancer cases. The mortality rate of the disease is around 0.9% of all cancer deaths, accounting for 87,000 deaths each year. Therefore, key manufacturers are actively involved in the development of immunotherapies targeting B-cell maturation antigen (BCMA) such as chimeric antigen receptor T-cells (CAR-T cells), bispecific antibodies, and antibody drug conjugates (ADCs). For instance, in 2012, the University of Pennsylvania and Novartis entered into an exclusive global research and licensing agreement to study and commercialize novel cellular immunotherapies using chimeric antigen receptor (CAR) technologies. In 2016, Juno Therapeutics entered into a licensing agreement with Memorial Sloan Kettering Cancer Center (MSKCC) and Eureka Therapeutics for developing CAR T cell immunotherapy against multiple novel targets. Drug Discovery Market - Regional Insights: North America accounted for the largest share in the drug discovery market, followed by Europe market in 2016. This is attributed to presence of a large number of top pharmaceutical and biotech companies, Pfizer, Inc., Merck, GlaxoSmithKline, Novartis and many more in this region. Furthermore, favorable regulatory framework and regulatory policies for investors for research and development of new drugs augments growth of drug discovery market in the region. The US Regulatory Framework provides for 3 distinct regulatory approval pathways outlined in the Food, Drug, and Cosmetics Act (FD&C Act), which allows the registration of novel compounds, new drugs containing similar ingredients to previously approved products and generic copies of previously approved products in systematic way helping the pharmaceutical companies to gain approval over the new drugs. Browse Complete Report For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/drug-discovery-market-1631 Furthermore, several pharmaceutical and biotechnological companies are focusing on expanding in Asia Pacific region, to maximize on their R&D efforts as the Asia Pacific region provides better access to patients for clinical trials, with lower cost operational efficiencies. Increasing government investment in research and development is also expected to foster growth of drug discovery in Asia Pacific region. For instance, in March 2011, the Korean government participated in the Korean National Enterprise for Clinical Trials, to advance the country’s infrastructure for conducting clinical trials, which could fasten the process of clinical trials, in turn supporting the growth of drug discovery market. Drug Discovery Market - Competitive Analysis:
About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected] Stethoscope is an acoustic medical device used for auscultation based physical examination of an animal or humans. The resonator placed beneath the small disc at one end amplifies sound of lungs, heart, esophagus or fetal heart rate. Stethoscope is a fundamental component of physical examination for a healthcare profession. Major drivers for growth of the stethoscope market are increasing incidence of cardiovascular disease, rising number of healthcare professionals, and improving healthcare facilities. Moreover, market players are introducing more user friendly technologically advanced products with Bluetooth connectivity or wireless digital stethoscope, which is expected to boost growth of the stethoscope market.
Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1613 Stethoscope Market Drivers: Increasing product launches by key players with advanced technologies is expected to aid in growth of the global stethoscope market during the forecast period. For instance, in March 2018, a research team developed an open-source, clinically validated template for a 3D printed stethoscope for application in the areas that have limited access to medical supplies. Moreover, in April 2018, Steth IO launched digital stethoscope named Steth IO. The product is built directly into the protective case of the physician’s iphone. It runs on an app that allows visualization of heart or lung sounds directly on the phone’s screen, when held against patient’s chest. Furthermore, it enables physician to store the records in the app, which can be shared in case of a second opinion. Steth IO received FDA approval in 2016. In 2015, Eko received US FDA clearance to launch Eko Core, a next generation digital stethoscope. In January 2018, M3DICINE Inc., a designer of intelligent medical devices, launched Stethee, the first Artificially Intelligent (AI)-enabled stethoscope system. The Stethee system include three products, which are Stethee Pro for medical and healthcare professionals, Stethee Vet for veterinarians and animal professionals, and Stethee Edu developed as educational and research tool. All these product launches are technologically advanced versions of conventional stethoscope and is expected to increase choices for the users. High incidence of heart diseases is expected to be another factor for growth of the market. Stethoscope is an important component that aids clinicians in diagnosis of cardiovascular disease, which affects 1 in 4 people in US, according to Center for Disease Control and Prevention (CDC). According to American Heart Association, 2018, cardiovascular disease is the leading cause of death, globally. Furthermore, according to same source, it is estimated that everyday 2,300 people in the U.S. die of cardiovascular disease, which means on an average 1 death per 38 seconds. Moreover, increasing geriatric population, who are more prone to diseases rising the demand for frequent diagnosis under several medical conditions expected to propel the growth of stethoscope market. For instance, the global geriatric population is estimated to be 962 million, which comprises 13% of the total global population, in 2017 as per United Nation Organization. According to their forecast, this geriatric population worldwide is expected to be reach 1.4 billion in 2030 and 2.1 billion by 2050. Stethoscope Market - Regional Analysis: Based on geography, the stethoscope market has been segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds the dominant position in stethoscope market, owing to the increasing number of new product launches by the key players in U.S. North America market is followed by Europe attributed to the increasing number of hospitals and clinics and medical professionals. For instance, according to Eurostat, around 1.8 million physicians are working in the European Union, while the comparison between 2005 and 2015 showed that the number of medical doctors graduating per 100,000 inhabitants rose to 12.4 medical doctors in 2015 as compared to 2005 (9.5 medical doctors per 100,00 inhabitants). Stethoscope Market – Competitive Lanscape:
By Product Type
About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected] Mechanical ventilation is a process that helps patients breathe by assisting inhalation of oxygen and exhalation of carbon dioxide through lungs with the help of specialized machines known as mechanical ventilators, respirators or breathing machines. These ventilators are connected to the patients by placing it into the mouth or nose and goes down into the windpipe, whereas some patients undergo surgery to have a hole through which the ventilation pipe can be passed. Mechanical ventilation is a life support treatment that assists the patient with critical health conditions to breathe just enough for the survival. Patients on mechanical ventilators are monitored in an intensive care unit (ICU) settings, which is hooked up to a monitor that measures respiratory rate, blood pressure, heart rate, oxygen saturation, and other critical parameters required for the survival of the patients. The mechanical ventilators does not heal the patient, however, it allows the patient to be stable during the medications and treatments. Healthcare professionals always try to get rid of patients from being monitored on ventilators, as there is a lot of risk involved in it. The process of getting a patient off from the ventilator is termed as weaning.
Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1605 Market Dynamics: Rising number of admissions in the intensive care units for continuous monitoring of critical and severely ill patients is expected to boost the market growth. For instance, according to the American Association for the Surgery of Trauma, in 2011, 790,257 hospitalizations involving mechanical ventilation were reported. In 2015, the Centers for Disease Control & Prevention (CDC) stated that acute injury and chronic obstructive pulmonary diseases (COPD) are major disorders responsible for ICU admissions. According to the results of Burden of Obstructive Lung Disease (BOLD) 2014, a multinational study to find prevalence of COPD reported that the prevalence of COPD in Germany was 5.9%, 19.1% in South Africa, and 11.9% in Mexico City of the total country’s population. Moreover, the rise in geriatric population suffering from slow recovery process of various chronic diseases is expected to augment growth of the global mechanical ventilators market. For instance, according to the National Council of Aging, in 2014, around 80% of the adults in the U.S. suffer from at least one chronic condition. The rising demand for emergency treatment of prolonged illness is also expected to drive growth of global mechanical ventilators market. However, high costs of the devices and shrinking profit margins of the major market players are expected to hinder the market growth. Regional Insights: On the basis of region, the global mechanical ventilators market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds a dominant position in the global mechanical ventilators market and is expected to retain its dominance over the forecast period, owing to rising number of patient admissions in emergency wards due to critical health conditions and severe injuries that require external support for survival. For instance, according to the Society of Critical Care Medicine, in 2015, over 5.7 million patients were admitted to the intensive care units (ICU) in the U.S. for intensive or invasive monitoring, airway support, stabilization of chronic medical problems, and breathing disorders. Furthermore, Asia Pacific is expected to witness a significant growth in the market, owing to developments in healthcare infrastructure, rising awareness among patients and manufacturers, and development of innovative and cost efficient solutions. For instance, in September 2017, the department of Neurology at the All India Institute of Medical Sciences (AIIMS) developed a portable life supporting ventilator that is 450 times smaller than the conventional counterparts and multiple times cheaper than the price of normal mechanical ventilators. Competitive Insights: The key players operating in the global mechanical ventilators market include Becton, Dickinson & Company, Mindray Medical International Limited, Getinge Group, GE Healthcare, Hamilton Medical AG, Medtronic Plc, Smiths Medical, Draeger Medical GmbH, Philips Respironics, Maquet Medical Systems GmbH, and others. Market players are focused towards providing technologically advanced products to sustain their presence in the market. For instance, in 2016, Maquet Medical Systems introduced two new ventilators named SERVO-U and SERVO-n that provides user-friendly interface to the clinicians dedicated to neonatal intensive care solution. Inquire Here Before Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1605 Market Taxonomy: On the basis of product type, the global mechanical ventilators market is segmented into:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected] Surgical staplers are used to close skin wounds, connect or remove parts of the bowels or lungs, and close post-surgery wounds as they are typically faster to apply than suturing. Using staplers reduces the local inflammatory response, width of the wound, and stapled lines are consistent and accurate compared to sutures. Use of staplers in anastomosis maintains consistency and technical failures is a rarity. Moreover, staplers can be used at difficult positions. Increasing demand for surgical staplers over conventional sutures will reduce risks associated to post-surgery infections and improve patient outcomes. FDA regulates surgical staplers under medical device category and oversees any adverse events that occur during its use. Surgical staplers are either disposable or made of plastic, while some are reusable and made of stainless steel.
Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1318 The global surgical staplers market was valued at US$ 2.8 billion in 2017 and is expected to witness a robust CAGR of 7.1% over the forecast period (2017 – 2025). Market Dynamics: The major factors driving growth of the surgical staplers market include rising geriatric population and increasing prevalence of obesity requiring surgical procedures. Bariatric surgery is a group of surgical weight loss procedures aimed to help obese people. As the prevalence of obesity is growing, there is also a proportionate surge in the number of people undergoing weight loss surgeries. For instance, according to the American Society for Metabolic and Bariatric surgery report 2016, the total number of bariatric surgery completed in the U.S. in year 2011 was 158,000. Technological advancements have led to development of various unique surgical instruments and devices. For instance, the MicroCutter 5/80 launched by Dextera Surgical Inc. in 2016, is the world’s first and only 5mm surgical stapler that articulates to 80 degrees in each direction. Introduction of new products and continuing technical developments in existing products are changing the way conventional surgeries are performed. However, strict regulatory landscape, high associated cost, and wide availability of alternative techniques such as sutures can hamper the market growth. Increasing number of surgeries to augment market growth: Increasing number of surgical procedures demanding surgical staplers is expected to be a major factor driving the global surgical staplers market over the forecast period. Staples are commonly used in surgical specialties such as cardiothoracic, gynecological, gastrointestinal, head, orthopedic, hand, urologic and vascular surgery. With an increase in chronic non-communicable disorders such as thoracic and cardiac diseases, there is a simultaneous rise in associated interventions required to treat these disorders. For instance, according to the Japanese Association for Thoracic Surgery (JATS), in 2017, over 30,000 lung cancer operations are carried out each year. Moreover, the number of cases of spontaneous pneumothorax continues to increase, reaching just over 10,000 cases each year, making the total number of thoracic operations in Japan around 70,000 every year. rising geriatric population and increasing occurrences of long-lasting ailments due lifestyle induced disorders are the other pivotal factors driving the global surgical staplers market. Elderly individuals are very susceptible to a wide range of chronic disorders. The global population is increasing in number and the proportion of geriatric population is also rising simultaneously. According to a study published in 2016, it is projected that around 16% of the global population will be aged over 65 years by 2050. Another projection by the U.S. Census shows that over 16% of the American population is likely to be older than 65 years of age by 2020. Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1318 The major players operating in the global surgical staplers market include B. BRAUN MELSUNGEN AG, CONMED Corporation, Dextera Surgical Inc., Frankenman International Ltd., Grena Ltd., Intuitive Surgical Inc., Johnson & Johnson, Medtronic Plc, Purple Surgical and Surkon Medical. Detailed Segmentation:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected] A liquid biopsy is a simple and non-invasive technique that enables to discover a range of information about a tumor through a simple blood sample. Some of the commercially available liquid biopsy tests for cancer are Cologurad, Guardant360, Oncotype SEQ Liquid Select, and Target Selector liquid biopsy assays. A liquid biopsy test can detect epidermal growth factor receptor (EGFR) gene mutations, evident in non-small cell lung cancer (NSCLC). The process requires only 5 milliliters of blood and is quicker than a surgical biopsy. The blood sample is processed to get 2 milliliters of plasma that is analyzed for tumor DNA. Potential of liquid biopsies to detect disease progression or treatment resistance long before it would trigger clinical symptoms or appear on imaging scans is major factor driving growth of liquid biopsy market.
Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1223 Market Dynamics: Factors such as rising prevalence of various cancers, rising demand for minimally invasive procedures, and advantages offered by liquid biopsy over conventional tissue biopsy are supporting growth of the liquid biopsy market. Liquid biopsy offers advantages over conventional tissue biopsy such as early disease detection, real-time monitoring of the metastasis and actual treatment response, detection of primary tumors and metastasis through simple and non-invasive tests, and may be cheaper than conventional biopsy. Furthermore, prevalence of various cancers is increasing and according to National Cancer Institute, 2016, an estimated 16.8 million new cases of cancer are diagnosed in the U.S., with an around 595,690 deaths from the disease. The number of people with cancer is expected to rise to 19 million by 2024, indicating need for early disease diagnosis and treatment. Demand for minimally invasive treatments is also increasing as tissue biopsy is an invasive approach for cancer diagnosis, wherein, liquid biopsy is more convenient, which is expected to boost growth of the liquid biopsy market. Rising applications of liquid biopsy owing to its advantages over conventional biopsy is expected to boost growth of the liquid biopsy market: Liquid biopsy offer efficient disease management as well as non-invasive prenatal testing (NIPT). NIPT enables diagnosis of potential risks of developing chromosomal abnormalities such as Edwards’s syndrome, Down syndrome, and X and Y chromosome abnormalities. Liquid biopsy offers complete genetic profile of the patient by providing DNA for more than one tumor. The process is non-invasive and provides no biases in results, owing to heterogeneity of the tumor tissues. The process requires small amount of sample and is cost and time effectiveness. Furthermore, applications of liquid biopsy for diagnosis of non-small cell lung cancer (NSCLC), breast cancer, coronary heart disease, prostate cancer, and others is expected to propel growth of the market. For instance, according to a new study published in Oncology Journal, in January 2018, the liquid biopsy combo involving exosomal RNA and cell-free DNA (cfDNA) improved the sensitivity of epidermal growth factor mutations in NSCLC. Furthermore, OncoCyte Corporation presented positive data from its breast cancer diagnostic test study, in December 2017, at San Antonio Breast Cancer Symposium. The global liquid biopsy market was valued at US$ 1,824.7 million in 2016 and is expected to witness a robust CAGR of 18.3% over the forecast period (2017–2025). Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1223 Some major players operating in the liquid biopsy market include Illumina, Inc., Roche AG, Natera, Inc., Laboratory Corporation of America Holdings (LabCorp), Qiagen N.V., Thermo Fisher Scientific Inc., Exact Sciences Corp., Biocept, Inc., Genomic Health, Inc., Guardant Health, TrovaGene Inc., CareDx Inc., Adaptive Biotechnologies Corporation, and Biocartis SA. Detailed Segmentation:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected] A liquid biopsy is a simple and non-invasive technique that enables to discover a range of information about a tumor through a simple blood sample. Some of the commercially available liquid biopsy tests for cancer are Cologurad, Guardant360, Oncotype SEQ Liquid Select, and Target Selector liquid biopsy assays. A liquid biopsy test can detect epidermal growth factor receptor (EGFR) gene mutations, evident in non-small cell lung cancer (NSCLC). The process requires only 5 milliliters of blood and is quicker than a surgical biopsy. The blood sample is processed to get 2 milliliters of plasma that is analyzed for tumor DNA. Potential of liquid biopsies to detect disease progression or treatment resistance long before it would trigger clinical symptoms or appear on imaging scans is major factor driving growth of liquid biopsy market.
Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1223 Market Dynamics: Factors such as rising prevalence of various cancers, rising demand for minimally invasive procedures, and advantages offered by liquid biopsy over conventional tissue biopsy are supporting growth of the liquid biopsy market. Liquid biopsy offers advantages over conventional tissue biopsy such as early disease detection, real-time monitoring of the metastasis and actual treatment response, detection of primary tumors and metastasis through simple and non-invasive tests, and may be cheaper than conventional biopsy. Furthermore, prevalence of various cancers is increasing and according to National Cancer Institute, 2016, an estimated 16.8 million new cases of cancer are diagnosed in the U.S., with an around 595,690 deaths from the disease. The number of people with cancer is expected to rise to 19 million by 2024, indicating need for early disease diagnosis and treatment. Demand for minimally invasive treatments is also increasing as tissue biopsy is an invasive approach for cancer diagnosis, wherein, liquid biopsy is more convenient, which is expected to boost growth of the liquid biopsy market. Rising applications of liquid biopsy owing to its advantages over conventional biopsy is expected to boost growth of the liquid biopsy market: Liquid biopsy offer efficient disease management as well as non-invasive prenatal testing (NIPT). NIPT enables diagnosis of potential risks of developing chromosomal abnormalities such as Edwards’s syndrome, Down syndrome, and X and Y chromosome abnormalities. Liquid biopsy offers complete genetic profile of the patient by providing DNA for more than one tumor. The process is non-invasive and provides no biases in results, owing to heterogeneity of the tumor tissues. The process requires small amount of sample and is cost and time effectiveness. Furthermore, applications of liquid biopsy for diagnosis of non-small cell lung cancer (NSCLC), breast cancer, coronary heart disease, prostate cancer, and others is expected to propel growth of the market. For instance, according to a new study published in Oncology Journal, in January 2018, the liquid biopsy combo involving exosomal RNA and cell-free DNA (cfDNA) improved the sensitivity of epidermal growth factor mutations in NSCLC. Furthermore, OncoCyte Corporation presented positive data from its breast cancer diagnostic test study, in December 2017, at San Antonio Breast Cancer Symposium. The global liquid biopsy market was valued at US$ 1,824.7 million in 2016 and is expected to witness a robust CAGR of 18.3% over the forecast period (2017–2025). Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1223 Some major players operating in the liquid biopsy market include Illumina, Inc., Roche AG, Natera, Inc., Laboratory Corporation of America Holdings (LabCorp), Qiagen N.V., Thermo Fisher Scientific Inc., Exact Sciences Corp., Biocept, Inc., Genomic Health, Inc., Guardant Health, TrovaGene Inc., CareDx Inc., Adaptive Biotechnologies Corporation, and Biocartis SA. Detailed Segmentation:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected] Contrast Media/Contrast Agent Market Trends, Outlook, and Opportunity Analysis, 2018 - 20263/26/2019 Contrast media or contrast agent is used in medical imaging to enhance the image of body parts generated through X-rays, magnetic resonance imaging (MRI), computed tomography (CT), and ultrasound. These substances are momentarily used to change the way imaging tools or x-rays interact with the body. Contrast media or contrast agent help the physicians to diagnose the medical conditions by improving the visibility of blood vessels or tissues and specific organs. These substances are added into the body prior to an imaging scan to help distinguish certain structures or tissues of interest from the surrounding tissue. Contrast media or contrast agent can be administered into the body in one of the four ways which include by enema (given rectally), orally, urethral, and by injecting into a blood vessel.
Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/1210 Rise in the gas micro bubble technology in MRI imaging is expected to boost the growth of contrast media/contrast agent market: The major factors driving the growth of contrast Media/contrast agent are the use of advanced technology such as gas micro bubble technology in MRI imaging, rising incidence of chronic diseases such as cardiac diseases, gastrointestinal disorders, and cancer. Advancements in medical imaging technology and increasing demand for image guided procedures and diagnostics is fueling the growth of the market. According to the International Agency for Research on Cancer (IARC), in 2012, an estimated 14.1 million new cancer cases and 8.2 million cancer deaths were recorded worldwide and by 2030 the number is expected to escalate to 21.7 million for new cancer cases and 13 million cancer deaths. However, side effects of contrast agents such as kidney diseases and high cost associated with the contrast media injectors are some of the factors that are hindering the growth of contrast media/ contrast agent market. Increasing incidence of cancer and cardiac disorders is expected to dominate North America region in contrast media/contrast agent market: On the basis of region, the global contrast media/contrast agent market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America dominates the contrast media/ contrast agent in the global market, followed by Europe. Improved MRI techniques in cardiovascular diseases, rise in the number of cancer and cardiac disorders, advancements in diagnostic technology, image guided surgical procedures are the factors that has propelled the growth of contrast media/contrast agent market in the North America region. According to the National Cancer Institute, in 2016, an estimated 1,685,210 new cases of cancer were diagnosed in the U.S. Also, according to the Centers for Disease Control and Prevention (CDC), 2017, an estimated 28.4 million heart cases were diagnosed in the U.S. Key players operating in the market: In March, 2017, GE Healthcare has launched Clariscan, a gadolinium based contrast agent designed to support effective visualization of abnormalities in the spine, brain and associated tissues. Clariscan, also known to be a gold standard detection tool in MR imaging, allows prompt detection of abnormalities by helping in improving contrast between pathological and normal tissue. The key players operating in the contrast media/contrast agent market include Lantheus Medical Imaging, GE Healthcare, Bayer HealthCare, Bracco Imaging S.p.A, NanoPET Pharma GmbH, Guerbet Group, CMC Contrast AB, Daiichi Sankyo, and Subhra Pharma Private Limited. Inquire Here Before Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1210 Contrast Media/ Contrast Agent Market Taxonomy: Contrast Media/ Contrast Agent Market is segmented on the basis of media type, route of administration, indication, end user and geography. On the basis of media type, contrast media/contrast agent market is segmented into:
About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected] Orthopedics is the branch of surgery concerned with conditions involving the musculoskeletal system. The branch is characterized by both surgical and nonsurgical means to treat musculoskeletal trauma, spine diseases, sports injuries, degenerative diseases, infections, tumors, and congenital disorders. Procedures such as dissection, fixation, shaping, cutting, and fragmentation in orthopedic procedures are performed with the help of instruments and accessories powered with electricity. Moreover, several of these tools are pneumatic that are powered using nitrogen or compressed air. Pneumatic-powered tools are easy to handle as they are small, vibration free, and light in weight. Orthopedic power tools facilitate accuracy and speed while performing orthopedic surgeries. Light-weight, highly modular, easy-to-assemble, and user friendly orthopedic power tools are easier to handle as compared to conventional heavy tools. Such properties of orthopedic power tools are contributing to positive growth of the orthopedic power tools market.
Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/1161 Market Dynamics: Major factors responsible for growth of orthopedics power tools market include increasing number of orthopedic surgeries coupled with shortage of skilled and trained surgeons. According to Becker’s Ambulatory Surgical Centre Review, in 2011, total of 5.3 million orthopedic surgeries were performed and this number was projected to rise to 6.6 million by 2020. This high prevalence rate is expected to fuel demand for orthopedic power tools for orthopedic surgical procedures in the near future. Other factors such as new product launches and advancement in technology in these devices is also contributing to the market growth. For instance, in March 2017, Stryker Corporation introduced range of instruments under brand name System 8 Power Tool. The tool has advanced System 8 SABO sagittal saw and System 8 cordless drivers for better accuracy and efficiency. However, contamination in the reusable devices, pricing pressure on manufacturers, and unfavorable reimbursement scenario are expected to restrain the market growth. For instance, according to CDC in 2011, the prevalence of healthcare associated infection were estimated at 157,500 surgical site infections in inpatient surgeries. Global orthopedic power tools market growth is driven by advancements in technology and rise in orthopedic surgeries: High prevalence of osteoporosis and increasing orthopedic surgeries are major factors driving growth of the global orthopedic power tools market. According to the International Osteoporosis Foundation, in 2014, 200 million individuals suffered from osteoporosis. Similarly, according to Becker’s Ambulatory Surgical Centre Review, in 2011, around 5.3 million orthopedic surgeries were performed and the number was projected to reach 6.6 million by 2020. Such high prevalence rate of osteoporosis and orthopedic surgeries is expected to fuel demand for orthopedic power tools over the forecast period. Advancement in technology and increasing geriatric population is expected to propel growth of the market. For instance, in March 2017, Stryker Corporation introduced a range of instruments under the brand name System 8 Power Tool. The tool is used for orthopedic applications and includes advanced System 8 SABO sagittal saw and System 8 cordless drivers that offer better accuracy and are more efficient. However, contamination of sterile instruments, increasing expanse associated with manufacturing of orthopedic power tools, and stringent government regulations are factors hindering growth of the orthopedic power tools market. The standard registration fees by FDA for larger companies manufacturing medical devices has increased by 33% in 2018 with the 510(k) application fees rising by 125%. The global orthopedic power tools market was valued at US$ 829.63 million in 2016 and is expected to exhibit a robust CAGR of 3.3% over the forecast period (2017–2025). Competative Analysis: Key players operating in the global orthopedic power tools market include Stryker Inc., Zimmer Holdings Inc., Misonix Inc., Arthrex, Aesculap, ConMed Corporation, DePuy Synthes, Brasseler, Medtronic, MedicMicro, B. Braun, OsteoMed, and Aygun Surgical Instruments. Inquire Here Before Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1161 Detailed Segmentation:
About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected] |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
April 2019
Categories |